The high cost of incretin mimetics for weight management limits insurance coverage and potentiates variation in utilization management strategies to control near-term spending.
Lauren Oshman, MD, MPH, DABOM
Advertisement
Articles by Lauren Oshman, MD, MPH, DABOM
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
2
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
3
5 FAQs: Ebola Outbreaks and the Challenge of Public Trust
4
Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered
5